ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia
Jean Carlos Lipreri da Silva,
Juan Luiz Coelho-Silva,
Hugo Passos Vicari,
Keli Lima,
Eduardo Magalhães Rego,
Fabiola Traina,
João Agostinho Machado-Neto
Affiliations
Jean Carlos Lipreri da Silva
Institute of Biomedical Sciences, University de São Paulo (USP), São Paulo, SP, Brazil
Juan Luiz Coelho-Silva
Hematology and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMUSP), Ribeirão Preto, SP, Brazil
Hugo Passos Vicari
Institute of Biomedical Sciences, University de São Paulo (USP), São Paulo, SP, Brazil
Keli Lima
Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology Hospital das Clínicas, Faculdade de Medicina, Universidade de Sao Paulo, (LIM-31 - HCFMUSP) Sao Paulo, SP, Brazil
Eduardo Magalhães Rego
Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology Hospital das Clínicas, Faculdade de Medicina, Universidade de Sao Paulo, (LIM-31 - HCFMUSP) Sao Paulo, SP, Brazil
Fabiola Traina
Hematology and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMUSP), Ribeirão Preto, SP, Brazil
João Agostinho Machado-Neto
Institute of Biomedical Sciences, University de São Paulo (USP), São Paulo, SP, Brazil; Corresponding author at: Department of Pharmacology, Institute of Biomedical Sciences of University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil.
